首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors.
【2h】

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors.

机译:内皮素-1在豚鼠肺中的急性促炎作用:ETA和ETB受体的参与。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. Although recent observations suggest that endothelin-1 (ET-1) may play a role in the pathogenesis of asthma, to date little is known about the effects of ET-1 on parameters other than bronchoconstriction. The objectives of the present experiments were to study whether intravenously administered ET-1 could exert pro-inflammatory actions in the guinea-pig lung and to assess the involvement of endothelin ETA and ETB receptors in these events by using the ETA receptor-selective antagonist, FR 139317, the novel ETA/ETB receptor antagonist, bosentan and the ETB receptor-selective agonist, IRL 1620. 2. Bolus i.v. injection of ET-1 (0.1-1 nmol kg-1) to anaesthetized guinea-pigs evoked dose-dependent increases in mean arterial blood pressure which lasted for 6-12 min. This was accompanied by a dose-dependent haemoconcentration (8-15% plasma volume losses) and increases (up to 546%) in albumin extravasation in the trachea, upper and lower bronchi, but not in the pulmonary parenchyma. Qualitatively similar changes were observed following i.v. injection of the ETB receptor agonist, IRL 1620 (0.3 and 1 nmol kg-1), although IRL 1620 appeared to be about 3 times less potent than ET-1. The ETA receptor-selective antagonist, FR 139317 (2.5 mg kg-1) inhibited the ET-1 (1 nmol kg-1)-induced pressor response, haemoconcentration and albumin extravasation by 75, 77 and 60-70%, respectively, whereas it did not attenuate IRL 1620 (1 nmol kg-1)-induced changes. The ETA/ETB receptor antagonist, bosentan (10 mg kg-1) almost completely inhibited the pressor, haemoconcentration and permeability effects of both ET-1 and IRL 1620. 3. ET-1, but not IRL 1620 (0.1-1 nmol kg-1), produced a dose-dependent neutropenia with relative lymphocytosis and monocytosis, but did not induce influx of neutrophil granulocytes into pulmonary tissues or the bronchoalveolar space. ET-1 (1 nmol kg-1)-induced neutropenia was prevented by pretreatment of the animals with FR 139317 (2.5 mg kg-1), bosentan (10 mg kg-1) or adrenaline (90 nmol kg-1), indicating that ET-1 caused intravascular sequestration of neutrophil granulocytes. 4. ET-1 or IRL 1620 (10(-10)-10(-6) M) alone did not activate alveolar macrophages in vitro, whereas at a concentration of 10(-8) M, ET-1, but not IRL 1620, markedly potentiated superoxide production in response to f-Met-Leu-Phe (10(-9)-10(-7) M) and platelet-activating factor (PAF, 10(-9)-10(-7) M), but not to phorbol 12-myristate 13-acetate (10(-9) M).(ABSTRACT TRUNCATED AT 400 WORDS)
机译:1.尽管最近的观察表明内皮素-1(ET-1)可能在哮喘的发病机制中起作用,但迄今为止,关于ET-1对除支气管收缩以外的其他参数的影响知之甚少。本实验的目的是研究静脉注射的ET-1是否可以在豚鼠肺中发挥促炎作用,并通过使用ETA受体选择性拮抗剂评估内皮素ETA和ETB受体在这些事件中的参与, FR 139317,新型ETA / ETB受体拮抗剂波生坦和ETB受体选择性激动剂IRL1620。2.静脉注射麻醉的豚鼠注射ET-1(0.1-1 nmol kg-1)引起剂量依赖性平均动脉血压升高,持续6-12分钟。这伴随着剂量依赖性的血药浓度(血浆体积损失8-15%),并且气管,上支气管和下支气管中白蛋白渗出增加(高达546%),但在肺实质中没有。静脉注射后观察到定性相似的变化。注射ETB受体激动剂IRL 1620(0.3和1 nmol kg-1),尽管IRL 1620的效力似乎比ET-1低3倍。 ETA受体选择性拮抗剂FR 139317(2.5 mg kg-1)分别抑制ET-1(1 nmol kg-1)诱导的升压反应,血药浓度和白蛋白外渗,分别为75%,77%和60-70%。它不会减弱IRL 1620(1 nmol kg-1)引起的变化。 ETA / ETB受体拮抗剂波生坦(10 mg kg-1)几乎完全抑制ET-1和IRL 1620的升压,血药浓度和通透性。3. ET-1,但不包括IRL 1620(0.1-1 nmol kg) -1)产生具有相对淋巴细胞增多和单核细胞增多的剂量依赖性中性粒细胞减少症,但不诱导嗜中性粒细胞流入肺组织或支气管肺泡间隙。通过用FR 139317(2.5 mg kg-1),波生坦(10 mg kg-1)或肾上腺素(90 nmol kg-1)预处理动物,可预防ET-1(1 nmol kg-1)诱导的中性粒细胞减少。 ET-1引起中性粒细胞粒细胞的血管隔离。 4.单独的ET-1或IRL 1620(10(-10)-10(-6)M)不能在体外激活肺泡巨噬细胞,而浓度为10(-8)M的ET-1却不激活IRL。 1620,对f-Met-Leu-Phe(10(-9)-10(-7)M)和血小板活化因子(PAF,10(-9)-10(-7)M的响应明显增强了超氧化物的产生),但不能佛波醇12肉豆蔻酸酯13乙酸酯(10(-9)M)。(摘要截短为400字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号